Related Experiment Videos
Mitomycin C as adjunctive therapy with glaucoma implant surgery
R Susanna1, M T Nicolela, W Y Takahashi
1Department of Ophthalmology, Albert Einstein Israelite Hospital, São Paulo, Brazil.
Ophthalmic Surgery
|July 1, 1994
Summary
Glaucoma implant surgery using a modified Molteno implant and mitomycin C effectively lowered intraocular pressure (IOP) in refractory glaucoma patients. This surgical approach shows promise for managing complex glaucoma cases.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Glaucoma Management
Background:
- Refractory glaucoma presents significant challenges for intraocular pressure (IOP) control.
- Standard treatments may be insufficient for severe or complex glaucoma cases.
Purpose of the Study:
- To evaluate the efficacy and safety of modified Molteno implant surgery combined with mitomycin C in patients with refractory glaucoma.
- To assess the impact on intraocular pressure and identify potential complications.
Main Methods:
- A cohort of 21 patients with refractory glaucoma underwent glaucoma surgery.
- The procedure involved the implantation of a modified Molteno device.
- Mitomycin C was applied intraoperatively to enhance surgical outcomes.
Main Results:
- A significant majority of eyes (76.2%) achieved an IOP of 21 mm Hg or less post-surgery.
- The mean follow-up period was 9.4 months, with six patients requiring additional IOP-lowering medication.
- Major complications included early flat anterior chamber (42.9%) and implant-related issues such as plate erosion (9.5%).
Conclusions:
- Glaucoma implant surgery with adjunctive mitomycin C appears to be a potentially useful treatment for refractory glaucoma.
- Careful patient selection and monitoring are essential due to the risk of complications.